Takeda Pharmaceutical Co Ltd: Q1 FY2025 Earnings Summary
Business Context and Reporting Period
This Form 6-K reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2025 (Q1 FY2025). The filing was submitted on July 30, 2025. Takeda operates as a single operating segment focused on the research, development, manufacturing, and marketing of pharmaceutical products.
Key Financial Metrics
| Metric | Q1 FY2025 (JPY Billion) | Q1 FY2024 (JPY Billion) | Change (AER) |
|---|---|---|---|
| Revenue | 1,106.7 | 1,208.0 | -8.4% |
| Operating Profit | 184.6 | 166.3 | +11.0% |
| Net Profit (Attributable to Owners) | 124.2 | 95.2 | +30.4% |
| Core Operating Profit | 321.8 | 382.3 | -15.8% |
| Basic EPS | 79.40 JPY | 60.71 JPY | +30.8% |
| Core EPS | 151 JPY | 176 JPY | -14.1% |
| Total Assets | 14,004.5 | 14,248.3 (Mar 2025) | -1.7% |
| Total Equity | 6,866.2 | 6,936.0 (Mar 2025) | -1.0% |
| Cash & Equivalents | 350.0 | 385.1 (Mar 2025) | -9.1% |
| Net Cash from Operating Activities | 215.4 | 170.3 | +26.5% |
Note: AER = Actual Exchange Rate. Core measures are non-IFRS metrics.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 8.4% (AER) primarily due to unfavorable foreign exchange rates and a significant drop in the Neuroscience segment (-35.7% AER) driven by generic erosion of VYVANSE in the U.S.
- Profitability Improvement: Despite lower revenue, Net Profit rose 30.4% due to a 36.2% reduction in income tax expenses and a 56.3% decrease in other operating expenses (lower restructuring costs).
- Core Performance: Core Operating Profit declined 15.8% (AER) and 11.9% (Constant Exchange Rate), reflecting the impact of VYVANSE patent cliffs and higher R&D costs in late-stage pipelines.
- Segment Highlights:
- Growth Areas: Gastroenterology (ENTYVIO), Rare Diseases (LIVTENCITY), and Plasma-Derived Therapies showed organic growth excluding FX impacts.
- Declining Areas: Neuroscience (VYVANSE) and Vaccines (QDENGA shipment timing) contributed to revenue misses.
- Balance Sheet: Total assets decreased slightly due to amortization and FX translation. Equity decreased primarily due to JPY 49.3 billion in treasury share acquisitions.
Guidance, Outlook, and Risks
- FY2025 Forecast (Unchanged):
- Revenue: JPY 4,530 billion (-1.1% vs prior year).
- Operating Profit: JPY 475 billion (+38.7% vs prior year).
- Net Profit: JPY 228 billion (+111.3% vs prior year).
- Core EPS: JPY 485 (-1.2% vs prior year).
- Management Guidance (CER Basis): Core Revenue, Core Operating Profit, and Core EPS are projected to be "Broadly Flat" for the full fiscal year.
- Key Assumptions: Forecasts assume global VYVANSE sales of JPY 241.0 billion (a 30% decline at CER). The forecast does not reflect potential impacts of U.S. tariffs on pharmaceutical products.
- Risks & Contingencies:
- FX Volatility: Significant fluctuations in foreign exchange rates could materially impact reported results.
- Patent Expirations: Continued generic competition for VYVANSE and other key products.
- Regulatory/Tariffs: Potential introduction of tariffs by the U.S. or other countries.
- Dividends: Projected annual dividend for FY2025 is JPY 200.00 per share (1st quarter: JPY 100.00).
Investor Verification Checklist
- VYVANSE Trajectory: Verify the sustainability of the 30% CER decline in VYVANSE sales and its long-term impact on the Neuroscience segment.
- Core vs. GAAP Divergence: Analyze the widening gap between GAAP Net Profit (+30.4%) and Core Operating Profit (-15.8%) to understand the impact of one-time items (tax benefits, restructuring savings, divestment gains).
- FX Sensitivity: Assess the exposure to USD/JPY and EUR/JPY fluctuations given the significant portion of revenue generated outside Japan.
- Debt Maturity Profile: Review the upcoming maturities of senior notes and commercial paper redemptions mentioned in the financing activities.
- R&D Pipeline: Evaluate the progress of late-stage pipelines cited as a driver for increased R&D expenses.